




	R ₁	R ₂	R ₃	R ₄
α-amanitin	OH	OH	NH ₂	OH
β-amanitin	OH	OH	OH	OH
γ-amanitin	H	OH	NH ₂	OH
ε-amanitin	H	OH	OH	OH
amanin	OH	OH	OH	H
amaninamide	OH	OH	NH ₂	H
amanullin	H	H	NH ₂	OH
amanullinic acid	H	H	OH	OH
γ-amanin	H	OH	OH	H
γ-amaninamide	H	OH	NH ₂	H

FIG. 1




FIG. 2






FIG. 3

A



B



C






FIG. 4


D



E





F



■ Untreated □ Maytansine (100nM) ▤ Amanitin (100nM)
▨ Her2-Amanitin (50nM) ▩ CD79b-Amanitin (50nM)

FIG. 4

**FIG. 5**

**FIG. 6**

ATAC	Cytotoxic activity in SKBR-3 EC50 [nM]	Cytotoxic activity in JIMT-1 EC50 [nM]	Cytotoxic activity in BT474 EC50 [nM]
α HER2-LALA-D265C-XIXb	7.05×10^{-3}	0.046	0.035
α HER2-LALA-D265C-XVIIIb	0.031	0.201	n.d.
α HER2-LALA-D265C-XIIIb	0.028	0.211	0.112
α HER2-LALA-D265C-XIIb	0.038	0.492	0.158
α HER2-LALA-D265C-XXIIb	0.158	-	0.378
α HER2-LALA-D265C-XXIb	0.152	-	0.217

Fig. 7




FIG. 8

Combination of anti-CD19 ATAC and PD-1 checkpoint inhibitor




Fig. 9




Fig. 10